In these trials, low doses (50 and 200 mg daily for 20 weeks) of EFV were used to activate CYP46A1 in individuals with early-stage AD (88), suggesting its potential as a therapeutic approach for neurodegenerative diseases. This evidence concerns the gene CYP46A1 and neurodegenerative disease.